Dmitry Medvedev Presented BIOCAD the First National “Industry” Award
ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ –
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia’s
first national “Industry” award to a biopharmaceutical company BIOCAD [http://biocad.ru/en
]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science
]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based
on monoclonal antibodies for treatment of cancer and autoimmune diseases. The ceremony
took place at the International Exhibition “Innoprom 2014″ in Ekaterinburg.
According to the Russian Ministry of Health, in the last 12 years the number of new
cases of malignant tumors has increased by 11%. The steady increase in the number of
cancer patients is a global trend. According to the International Agency for Research on
Cancer, in the next 20 years the number of new oncology patients in the world will reach
the figure of 22 million cases per year. Therefore, Russia and the rest of the world are
so desperately in need of new effective drugs that will help to overcome serious illnesses
and save millions of lives.
BIOCAD is developing a wide portfolio of innovative products based on monoclonal
antibodies for treatment of diseases such as breast cancer, colorectal cancer, lung
cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.
“Now the country is undergoing fundamental changes regarding availability of modern
drugs for its people. Thanks to the support of Ministry of Industry and Trade, Ministry of
Health, Ministry of Economic Development, Russian pharmaceutical companies are creating a
powerful technologic basis for the production of innovative products and are competing
successfully on the global pharmaceutical market. Of course, our foreign colleagues are
not happy with this. However, now we can deliver innovative medicines that have no
analogues in the world. The project MabNext is a bright example of this,” said Dmitriy
Morozov, CEO of BIOCAD.
The main advantage of products based on monoclonal antibodies, is that they affect
only selected cells or molecules, in other words, these are targeted therapies. Only
relevant targets are neutralized without affecting the healthy cells.
BIOCAD has more than 10 of such innovative products based on monoclonal antibodies at
different stages of development. One of the most noticeable ones is an antibody specific
for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no
analogues on the market and its characteristics are superior to anti-IL17 antibodies being
developed by foreign companies. This product has huge potential when it comes to the
treatment of socially significant diseases such as rheumatoid arthritis and psoriasis.
If we talk about cancer – the company is at the stage of developing original products
based on monoclonal antibodies against targets such as PD-1, HER3, Ang-2 and others.
Antibodies for PD-1 increase ability of patient’s immune system to recognize and destroy
Photo: http://photos.prnewswire.com/prnh/20140514/686712 http://photos.prnewswire.com/prnh/20140710/696843